Calquence head-to-head results versus ibrutinib
ELEVATE-RR head-to-head trial in previously treated patients showed less cardiovascular toxicity and fewer discontinuations due to adverse events for Calquence versus ibrutinib Long-term follow up from ELEVATE-TN trial in front-line setting showed Calquence maintained progression-free survival and favourable tolerability at four yearsFinal results from the head-to-head ELEVATE-RR Phase III trial of AstraZeneca’s Calquence (acalabrutinib) demonstrated non-inferior progression-free survival (PFS) and statistically significantly fewer events of atrial fibrillation versus ibrutinib in adults